Sharescart Research Club logo

Ajooni Biotech Overview

1. Business Overview

Ajooni Biotech Ltd. is an Indian company primarily engaged in the manufacturing and selling of various types of animal feed. Its core business model involves producing compound feed products, such as cattle feed, poultry feed, and potentially feed for other livestock or aquaculture, using a mix of agricultural raw materials and supplements. The company generates revenue by selling these feed products directly to farmers, dairy owners, poultry farms, and through a network of distributors. The aim is to provide nutritious and balanced feed to improve animal health, productivity, and yield for its customers.

2. Key Segments / Revenue Mix

The company's primary revenue stream is derived from the sale of animal feed products. While specific sub-segment contributions are not publicly available, it likely includes:

Cattle Feed: For dairy and beef cattle.

Poultry Feed: For broiler and layer chickens.

Given its industry focus, a vast majority, if not all, of its revenue comes from the animal feed segment.

3. Industry & Positioning

The Indian animal feed industry is characterized by a mix of organized national players and numerous regional and local manufacturers. It is a growing sector driven by increasing demand for animal protein, professionalization of livestock farming, and a shift towards compound feed. Ajooni Biotech Ltd. likely operates as a regional player, competing with both larger established companies that have national distribution networks and other local manufacturers. Its positioning would depend on its geographical presence, product specialization, and pricing strategy within specific states or districts in India.

4. Competitive Advantage (Moat)

Ajooni Biotech Ltd. is likely to have a limited competitive moat.

Brand: It may have established some regional brand recognition and loyalty among local farmers, but it is unlikely to possess a strong national brand moat against larger players.

Scale: While it might achieve some economies of scale within its operating regions, it likely doesn't have a significant scale advantage over large national competitors.

Distribution Network: A well-established local/regional distribution network and strong relationships with farmers and distributors could provide a minor advantage.

Switching Costs: Switching costs for farmers are generally low, as many feed products are interchangeable unless specific formulations offer demonstrably superior results.

Overall, competitive advantages are likely to be moderate, relying on product quality, pricing, and localized customer service.

5. Growth Drivers

Rising Demand for Animal Protein: India's growing population and increasing disposable incomes are fueling higher consumption of milk, eggs, and meat, consequently driving demand for animal feed.

Professionalization of Farming: A shift from traditional subsistence farming to commercial dairy, poultry, and aquaculture operations increases the demand for scientifically formulated, high-quality compound feed.

Government Support: Initiatives to boost the livestock and dairy sectors often provide a conducive environment for feed manufacturers.

Product & Geographical Expansion: Expanding the product portfolio to include new feed types (e.g., aquaculture feed) or increasing geographical reach can drive growth.

Improved Feed Efficiency: Farmers' increasing awareness about the economic benefits of better feed for higher yields and animal health.

6. Risks

Raw Material Price Volatility: Key inputs such as grains (maize, soy), oilseed meals, and other supplements are agricultural commodities subject to price fluctuations due to weather, government policies, and global supply-demand dynamics.

Intense Competition: The industry is highly competitive, leading to pricing pressures and potential erosion of margins from both large organized players and local unorganized manufacturers.

Disease Outbreaks: Outbreaks of animal diseases (e.g., bird flu, African Swine Fever) can severely impact livestock populations and, consequently, the demand for feed.

Regulatory Changes: Changes in regulations regarding feed quality, ingredients, or environmental norms can impact production costs and processes.

Weather Dependence: Adverse weather conditions can affect crop yields, impacting raw material availability and prices.

Credit Risk: Dependence on timely payments from farmers and distributors, especially in agricultural cycles.

7. Management & Ownership

Ajooni Biotech Ltd. is typically promoted and managed by its founding family, a common structure for many small and mid-sized companies in India. The vision, experience, and leadership quality of the promoters play a crucial role in the company's strategic direction and execution. Ownership is likely promoter-dominated, with public shareholders holding the remainder. The management team would typically include a mix of family members and professional managers overseeing operations, sales, and finance.

8. Outlook

Ajooni Biotech operates in a fundamentally growing sector driven by India's demographic and economic trends, particularly the increasing demand for animal protein. This provides a tailwind for the company's core business. The professionalization of farming practices also supports a shift towards organized compound feed. However, the business faces significant challenges including intense price competition, volatility in raw material costs, and the inherent risks associated with livestock farming such as disease outbreaks. The ability of Ajooni Biotech to manage raw material sourcing efficiently, expand its distribution network, maintain product quality, and potentially diversify its product offerings will be critical for sustained growth and profitability in a competitive and cyclical industry.

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Ajooni Biotech Key Financials

Market Cap ₹72 Cr.

Stock P/E 21.3

P/B 0.8

Current Price ₹4.2

Book Value ₹ 5.3

Face Value 2

52W High ₹6.6

Dividend Yield 0%

52W Low ₹ 3.6

Ajooni Biotech Share Price

| |

Volume
Price

Ajooni Biotech Quarterly Price

Show Value Show %

Ajooni Biotech Peer Comparison

Ajooni Biotech Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 19 20 20 26 26 34 29 31 32 59
Other Income 0 2 0 0 0 0 1 1 0 0
Total Income 20 22 20 26 26 34 31 32 32 59
Total Expenditure 19 21 18 25 25 33 28 31 30 56
Operating Profit 1 1 2 1 1 1 2 1 2 3
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 1
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1 1 1 1 1 1 2 1 1 2
Provision for Tax 0 0 1 0 0 0 0 0 0 1
Profit After Tax 0 0 1 0 1 1 2 1 1 2
Adjustments 0 0 0 0 0 -0 0 0 0 0
Profit After Adjustments 0 0 1 0 1 1 2 1 1 2
Adjusted Earnings Per Share 0 0.1 0.1 0 0 0 0.1 0 0.1 0.1

Ajooni Biotech Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 7 13 29 42 40 40 51 74 74 80 115 151
Other Income 0 0 0 0 0 0 0 0 0 2 2 2
Total Income 7 13 29 43 40 40 51 74 75 82 117 154
Total Expenditure 7 13 28 41 39 39 49 71 72 78 111 145
Operating Profit 0 0 1 1 1 1 2 3 3 4 6 8
Interest 0 0 0 0 0 0 1 1 0 1 0 0
Depreciation 0 0 0 0 0 0 1 1 1 1 1 1
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 0 0 0 0 0 1 1 2 3 4 6
Provision for Tax 0 0 0 0 0 0 0 0 0 1 1 1
Profit After Tax 0 0 0 0 0 0 0 1 1 2 3 6
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 0 0 0 0 0 0 0 1 1 2 3 6
Adjusted Earnings Per Share 0.2 0.3 0.5 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.3

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 44% 16% 24% 32%
Operating Profit CAGR 50% 26% 43% 0%
PAT CAGR 50% 44% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -29% -2% -13% NA%
ROE Average 5% 5% 5% 10%
ROCE Average 7% 7% 7% 12%

Ajooni Biotech Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 0 1 1 11 12 16 16 16 42 43 88
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 1 0 4 1 2 3 2 2 2
Other Non-Current Liabilities 0 -0 3 2 -0 -0 -0 -0 -0 -0 -0
Total Current Liabilities 1 2 8 6 2 6 10 10 15 3 5
Total Liabilities 2 2 13 19 18 23 28 29 58 47 95
Fixed Assets 0 0 1 1 1 2 4 6 6 10 11
Other Non-Current Assets 0 0 6 7 5 3 3 1 17 5 21
Total Current Assets 1 2 6 11 12 18 21 22 35 32 62
Total Assets 2 2 13 19 18 23 28 29 58 47 95

Ajooni Biotech Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 5 1 0 0 0 0 0
Cash Flow from Operating Activities 0 -1 0 0 -5 -4 1 4 -6 23 -18
Cash Flow from Investing Activities -0 -0 0 0 1 0 -3 -2 -16 8 -17
Cash Flow from Financing Activities 0 1 0 0 -1 3 2 -2 22 -4 25
Net Cash Inflow / Outflow 0 -0 0 0 -5 -1 0 -0 0 27 -10
Closing Cash & Cash Equivalent 0 0 0 0 1 0 0 0 0 27 -10

Ajooni Biotech Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.2 0.27 0.55 0.12 0.12 0.07 0.07 0.21 0.13 0.25 0.2
CEPS(Rs) 0.29 0.47 0.93 0.22 0.25 0.18 0.19 0.4 0.24 0.35 0.26
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 1.18 1.45 1.92 3.19 3.43 3.34 3.1 3.27 4.76 4.87 5.09
Core EBITDA Margin(%) 1.83 1.74 2.34 2.19 1.78 3.02 3.23 3.96 3.71 2.79 3.22
EBIT Margin(%) 1.49 1.22 1.84 1.97 1.53 2.02 2.13 2.7 2.76 4.43 4.07
Pre Tax Margin(%) 1.46 1.07 1.36 1.15 1.2 1.2 0.99 1.97 2.12 3.74 3.77
PAT Margin (%) 1.01 0.73 0.97 0.91 1.03 0.87 0.73 1.42 1.51 2.7 2.94
Cash Profit Margin (%) 1.45 1.27 1.64 1.65 2.14 2.1 1.86 2.73 2.86 3.79 3.89
ROA(%) 6.89 4.78 3.61 2.4 2.2 1.69 1.47 3.7 2.58 4.09 4.75
ROE(%) 18.72 20.38 36.98 6.8 3.72 2.54 2.4 6.58 3.87 5.12 5.18
ROCE(%) 27.57 18.62 36.19 10.03 3.84 4.35 5.07 9.09 5.99 7.75 6.94
Receivable days 22.49 27.7 16.1 17.94 35.36 79.67 94.23 67.91 84.26 76.34 46.43
Inventory Days 13.4 10.6 29.6 26.78 32.48 38.09 30.97 27.75 31.55 50.94 62.62
Payable days 36.96 31.05 45.37 29.93 10.48 16.19 31.11 34.78 46.94 30.34 9.55
PER(x) 0 0 0 37.96 23.11 14.32 63.36 49.93 27.12 21.09 28.6
Price/Book(x) 0 0 0 1.41 0.81 0.32 1.52 3.2 0.73 1.07 1.1
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.01 0.07 0.03 0.43 0.41 0.28 0.72 0.98 0.53 0.67 0.8
EV/Core EBITDA(x) 0.75 4.07 1.19 15.86 15.57 8.68 22.19 24.44 12.9 12.07 15.91
Net Sales Growth(%) 1166.04 83.46 115.71 48.51 -6.27 0.79 27.49 45.06 0.61 7.55 43.16
EBIT Growth(%) 785.95 50.37 224.98 59.38 -27.43 33.45 34.59 83.88 2.69 72.89 31.26
PAT Growth(%) 845.45 32.55 185.79 40 6.45 -15.62 7.57 181.14 7.24 92.16 56.02
EPS Growth(%) 845.45 32.55 103.17 -78.26 1.26 -38.2 0.44 180.97 -38.74 92.13 -20.63
Debt/Equity(x) 0 1.5 0.64 0.45 0.41 0.32 0.44 0.33 0.12 0.05 0.02
Current Ratio(x) 1.19 1.25 0.73 1.87 6.14 3 2.05 2.18 2.28 10.74 12.86
Quick Ratio(x) 0.89 1 0.22 1.56 3.54 2.43 1.53 1.6 1.82 5.63 7.89
Interest Cover(x) 63.06 7.94 3.84 2.41 4.63 2.47 1.86 3.71 4.3 6.38 13.95
Total Debt/Mcap(x) 0 0 0 0.25 0.39 0.79 0.22 0.08 0.15 0.04 0.02

Ajooni Biotech Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 26.44 26.44 26.89 26.89 26.89 26.89 26.89 26.89 26.89 26.89
FII 0 0 0 0.29 0.18 0 0 0 0 0
DII 0 0 0 0 0 0 0 0 0 0
Public 73.56 73.56 73.11 72.82 72.92 73.11 73.11 73.11 73.11 73.11
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Ajooni Biotech News

Ajooni Biotech Pros & Cons

Pros

  • Stock is trading at 0.8 times its book value
  • Debtor days have improved from 30.34 to 9.55days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 26.89%.
  • Company has a low return on equity of 5% over the last 3 years.
whatsapp